Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insmed (INSM) Other Accumulated Expenses (2016 - 2024)

Insmed's Other Accumulated Expenses history spans 14 years, with the latest figure at $8.5 million for Q3 2024.

  • Quarterly Other Accumulated Expenses rose 283.71% to $8.5 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Sep 2024, up 283.71% year-over-year, with the annual reading at $10.4 million for FY2023, 549.12% up from the prior year.
  • Other Accumulated Expenses came in at $8.5 million for Q3 2024, down from $8.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $10.4 million in Q4 2023 to a low of $78000.0 in Q1 2020.
  • The 5-year median for Other Accumulated Expenses is $2.4 million (2021), against an average of $4.9 million.
  • The largest YoY upside for Other Accumulated Expenses was 549.12% in 2023 against a maximum downside of 58.24% in 2023.
  • Insmed's Other Accumulated Expenses stood at $78000.0 in 2020, then soared by 2979.49% to $2.4 million in 2021, then plummeted by 33.56% to $1.6 million in 2022, then soared by 549.12% to $10.4 million in 2023, then fell by 17.7% to $8.5 million in 2024.
  • Per Business Quant, the three most recent readings for INSM's Other Accumulated Expenses are $8.5 million (Q3 2024), $8.6 million (Q2 2024), and $10.2 million (Q1 2024).